Semin Reprod Med 2014; 32(03): 202-213
DOI: 10.1055/s-0034-1371092
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Childhood Obesity and Its Impact on the Development of Adolescent PCOS

Amy D. Anderson
1   Center for Research in Reproduction, University of Virginia School of Medicine
2   Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine
,
Christine M. Burt Solorzano
1   Center for Research in Reproduction, University of Virginia School of Medicine
3   Division of Endocrinology and Metabolism, Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, Virginia
,
Christopher R. McCartney
1   Center for Research in Reproduction, University of Virginia School of Medicine
2   Division of Endocrinology and Metabolism, Department of Medicine, University of Virginia School of Medicine
› Author Affiliations
Further Information

Publication History

Publication Date:
08 April 2014 (online)

Abstract

Obesity exacerbates the reproductive and metabolic manifestations of polycystic ovary syndrome (PCOS). The symptoms of PCOS often begin in adolescence, and the rising prevalence of peripubertal obesity has prompted concern that the prevalence and severity of adolescent PCOS is increasing in parallel. Recent data have disclosed a high prevalence of hyperandrogenemia among peripubertal adolescents with obesity, suggesting that such girls are indeed at risk for developing PCOS. Obesity may impact the risk of PCOS via insulin resistance and compensatory hyperinsulinemia, which augments ovarian/adrenal androgen production and suppresses sex hormone–binding globulin (SHBG), thereby increasing androgen bioavailability. Altered luteinizing hormone (LH) secretion plays an important role in the pathophysiology of PCOS, and although obesity is generally associated with relative reductions of LH, higher LH appears to be the best predictor of increased free testosterone among peripubertal girls with obesity. Other potential mechanisms of obesity-associated hyperandrogenemia include enhanced androgen production in an expanded fat mass and potential effects of abnormal adipokine/cytokine levels. Adolescents with PCOS are at risk for comorbidities such as metabolic syndrome and impaired glucose tolerance, and concomitant obesity compounds these risks. For all of these reasons, weight loss represents an important therapeutic target in obese adolescents with PCOS.

 
  • References

  • 1 [Anonymous] ACOG Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin No. 108: polycystic ovary syndrome. Obstet Gynecol 2009; 114 (4) 936-949
  • 2 March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 2010; 25 (2) 544-551
  • 3 Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2010; 16 (4) 347-363
  • 4 Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 2012; 18 (6) 618-637
  • 5 McCartney CR, Prendergast KA, Chhabra S , et al. The association of obesity and hyperandrogenemia during the pubertal transition in girls: obesity as a potential factor in the genesis of postpubertal hyperandrogenism. J Clin Endocrinol Metab 2006; 91 (5) 1714-1722
  • 6 Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond) 2008; 32 (7) 1035-1041
  • 7 Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010. JAMA 2012; 307 (5) 483-490
  • 8 Alvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med 2006; 166 (19) 2081-2086
  • 9 Yildiz BO, Knochenhauer ES, Azziz R. Impact of obesity on the risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93 (1) 162-168
  • 10 Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 2012; 33 (6) 981-1030
  • 11 Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of obesity in the United States, 2009–2010. NCHS Data Brief 2012; 82: 1-8
  • 12 Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med 2012; 30 (6) 496-506
  • 13 Ezeh U, Yildiz BO, Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab 2013; 98 (6) E1088-E1096
  • 14 Escobar-Morreale HF, San Millán JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007; 18 (7) 266-272
  • 15 Barber TM, Golding SJ, Alvey C , et al. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008; 93 (3) 999-1004
  • 16 Mannerås-Holm L, Leonhardt H, Kullberg J , et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 2011; 96 (2) E304-E311
  • 17 Littlejohn EE, Weiss RE, Deplewski D, Edidin DV, Rosenfield R. Intractable early childhood obesity as the initial sign of insulin resistant hyperinsulinism and precursor of polycystic ovary syndrome. J Pediatr Endocrinol Metab 2007; 20 (1) 41-51
  • 18 Rosenfield RL. Clinical review: identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 2007; 92 (3) 787-796
  • 19 Christensen SB, Black MH, Smith N , et al. Prevalence of polycystic ovary syndrome in adolescents. Fertil Steril 2013; 100 (2) 470-477
  • 20 Laitinen J, Taponen S, Martikainen H , et al. Body size from birth to adulthood as a predictor of self-reported polycystic ovary syndrome symptoms. Int J Obes Relat Metab Disord 2003; 27 (6) 710-715
  • 21 Rich-Edwards JW, Goldman MB, Willett WC , et al. Adolescent body mass index and infertility caused by ovulatory disorder. Am J Obstet Gynecol 1994; 171 (1) 171-177
  • 22 Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006; 65 (2) 137-145
  • 23 Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproduction in women with polycystic ovary syndrome. BJOG 2006; 113 (10) 1148-1159
  • 24 Pinola P, Lashen H, Bloigu A , et al. Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study. Hum Reprod 2012; 27 (11) 3279-3286
  • 25 Strain GW, Zumoff B, Miller LK, Rosner W. Sex difference in the effect of obesity on 24-hour mean serum gonadotropin levels. Horm Metab Res 2003; 35 (6) 362-366
  • 26 Taponen S, Martikainen H, Järvelin MR , et al. Hormonal profile of women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland birth cohort 1966 study. J Clin Endocrinol Metab 2003; 88 (1) 141-147
  • 27 Randolph Jr JF, Sowers M, Gold EB , et al. Reproductive hormones in the early menopausal transition: relationship to ethnicity, body size, and menopausal status. J Clin Endocrinol Metab 2003; 88 (4) 1516-1522
  • 28 Lim SS, Norman RJ, Davies MJ, Moran LJ. The effect of obesity on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Rev 2013; 14 (2) 95-109
  • 29 Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril 2009; 92 (6) 1966-1982
  • 30 Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millán JL. The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2005; 90 (12) 6364-6369
  • 31 Eid GM, Cottam DR, Velcu LM , et al. Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005; 1 (2) 77-80
  • 32 Jamal M, Gunay Y, Capper A, Eid A, Heitshusen D, Samuel I. Roux-en-Y gastric bypass ameliorates polycystic ovary syndrome and dramatically improves conception rates: a 9-year analysis. Surg Obes Relat Dis 2012; 8 (4) 440-444
  • 33 Legro RS, Bentley-Lewis R, Driscoll D, Wang SC, Dunaif A. Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 2002; 87 (5) 2128-2133
  • 34 Reinehr T, de Sousa G, Roth CL, Andler W. Androgens before and after weight loss in obese children. J Clin Endocrinol Metab 2005; 90 (10) 5588-5595
  • 35 McCartney CR, Blank SK, Prendergast KA , et al. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab 2007; 92 (2) 430-436
  • 36 Wabitsch M, Hauner H, Heinze E , et al. Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after weight reduction. J Clin Endocrinol Metab 1995; 80 (12) 3469-3475
  • 37 Knudsen KL, Blank SK, Burt Solorzano C , et al. Hyperandrogenemia in obese peripubertal girls: correlates and potential etiological determinants. Obesity (Silver Spring) 2010; 18 (11) 2118-2124
  • 38 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18 (6) 774-800
  • 39 Yildiz BO, Azziz R. The adrenal and polycystic ovary syndrome. Rev Endocr Metab Disord 2007; 8 (4) 331-342
  • 40 Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 1999; 20 (4) 535-582
  • 41 Arslanian SA, Lewy VD, Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and beta-cell dysfunction and risk of cardiovascular disease. J Clin Endocrinol Metab 2001; 86 (1) 66-71
  • 42 Lewy VD, Danadian K, Witchel SF, Arslanian S. Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 2001; 138 (1) 38-44
  • 43 Bloch CA, Clemons P, Sperling MA. Puberty decreases insulin sensitivity. J Pediatr 1987; 110 (3) 481-487
  • 44 Moran A, Jacobs Jr DR, Steinberger J , et al. Insulin resistance during puberty: results from clamp studies in 357 children. Diabetes 1999; 48 (10) 2039-2044
  • 45 Roemmich JN, Clark PA, Lusk M , et al. Pubertal alterations in growth and body composition. VI. Pubertal insulin resistance: relation to adiposity, body fat distribution and hormone release. Int J Obes Relat Metab Disord 2002; 26 (5) 701-709
  • 46 Brufani C, Tozzi A, Fintini D , et al. Sexual dimorphism of body composition and insulin sensitivity across pubertal development in obese Caucasian subjects. Eur J Endocrinol 2009; 160 (5) 769-775
  • 47 Pilia S, Casini MR, Foschini ML , et al. The effect of puberty on insulin resistance in obese children. J Endocrinol Invest 2009; 32 (5) 401-405
  • 48 Vambergue A, Lautier C, Valat AS, Cortet-Rudelli C, Grigorescu F, Dewailly D. Follow-up study of two sisters with type A syndrome of severe insulin resistance gives a new insight into PCOS pathogenesis in relation to puberty and pregnancy outcome: a case report. Hum Reprod 2006; 21 (5) 1274-1278
  • 49 Chakrabarty S, Miller BT, Collins TJ, Nagamani M. Ovarian dysfunction in peripubertal hyperinsulinemia. J Soc Gynecol Investig 2006; 13 (2) 122-129
  • 50 Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000; 85 (10) 3526-3530
  • 51 Ibáñez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F. Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001; 86 (8) 3595-3598
  • 52 Glueck CJ, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). J Adolesc Health 2001; 29 (3) 160-169
  • 53 Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002; 87 (4) 1555-1559
  • 54 De Leo V, Musacchio MC, Morgante G, Piomboni P, Petraglia F. Metformin treatment is effective in obese teenage girls with PCOS. Hum Reprod 2006; 21 (9) 2252-2256
  • 55 McCartney CR. Maturation of sleep-wake gonadotrophin-releasing hormone secretion across puberty in girls: potential mechanisms and relevance to the pathogenesis of polycystic ovary syndrome. J Neuroendocrinol 2010; 22 (7) 701-709
  • 56 Apter D, Bützow T, Laughlin GA, Yen SS. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome. J Clin Endocrinol Metab 1994; 79 (1) 119-125
  • 57 McCartney CR, Prendergast KA, Blank SK, Helm KD, Chhabra S, Marshall JC. Maturation of luteinizing hormone (gonadotropin-releasing hormone) secretion across puberty: evidence for altered regulation in obese peripubertal girls. J Clin Endocrinol Metab 2009; 94 (1) 56-66
  • 58 Chang RJ, Laufer LR, Meldrum DR , et al. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab 1983; 56 (5) 897-903
  • 59 Steingold K, De Ziegler D, Cedars M , et al. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J Clin Endocrinol Metab 1987; 65 (4) 773-778
  • 60 Risma KA, Clay CM, Nett TM, Wagner T, Yun J, Nilson JH. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc Natl Acad Sci U S A 1995; 92 (5) 1322-1326
  • 61 Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf) 1994; 41 (4) 473-481
  • 62 Taylor AE, McCourt B, Martin KA , et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82 (7) 2248-2256
  • 63 Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 1997; 82 (11) 3728-3733
  • 64 Pagán YL, Srouji SS, Jimenez Y, Emerson A, Gill S, Hall JE. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. J Clin Endocrinol Metab 2006; 91 (4) 1309-1316
  • 65 Srouji SS, Pagán YL, D'Amato F , et al. Pharmacokinetic factors contribute to the inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome. J Clin Endocrinol Metab 2007; 92 (4) 1347-1352
  • 66 Jain A, Polotsky AJ, Rochester D , et al. Pulsatile luteinizing hormone amplitude and progesterone metabolite excretion are reduced in obese women. J Clin Endocrinol Metab 2007; 92 (7) 2468-2473
  • 67 Silfen ME, Denburg MR, Manibo AM , et al. Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents. J Clin Endocrinol Metab 2003; 88 (10) 4682-4688
  • 68 Bordini B, Littlejohn E, Rosenfield RL. Blunted sleep-related luteinizing hormone rise in healthy premenarcheal pubertal girls with elevated body mass index. J Clin Endocrinol Metab 2009; 94 (4) 1168-1175
  • 69 Anderson AD, Burt Solorzano C, Bhabhra R , et al. The role of hyperinsulinemia vs. insulin resistance in obese girls with hyperandrogenemia. 95th Meeting of the Endocrine Society, San Francisco, CA, June 15–18, 2013; Abstract SUN-505
  • 70 Burt Solorzano CM, Beller JP, Abshire MY, Collins JS, McCartney CR, Marshall JC. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids 2012; 77 (4) 332-337
  • 71 Chhabra S, McCartney CR, Yoo RY, Eagleson CA, Chang RJ, Marshall JC. Progesterone inhibition of the hypothalamic gonadotropin-releasing hormone pulse generator: evidence for varied effects in hyperandrogenemic adolescent girls. J Clin Endocrinol Metab 2005; 90 (5) 2810-2815
  • 72 Blank SK, McCartney CR, Chhabra S , et al. Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls—implications for regulation of pubertal maturation. J Clin Endocrinol Metab 2009; 94 (7) 2360-2366
  • 73 Brothers KJ, Wu S, DiVall SA , et al. Rescue of obesity-induced infertility in female mice due to a pituitary-specific knockout of the insulin receptor. Cell Metab 2010; 12 (3) 295-305
  • 74 Dunaif A, Mandeli J, Fluhr H, Dobrjansky A. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome. J Clin Endocrinol Metab 1988; 66 (1) 131-139
  • 75 Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SS. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab 1996; 81 (8) 2854-2864
  • 76 Rosenfield RL, Bordini B. Evidence that obesity and androgens have independent and opposing effects on gonadotropin production from puberty to maturity. Brain Res 2010; 1364: 186-197
  • 77 Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986; 62 (5) 904-910
  • 78 Gilling-Smith C, Willis DS, Beard RW, Franks S. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994; 79 (4) 1158-1165
  • 79 Nelson VL, Legro RS, Strauss III JF, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol 1999; 13 (6) 946-957
  • 80 Rosenfield RL. Ovarian and adrenal function in polycystic ovary syndrome. Endocrinol Metab Clin North Am 1999; 28 (2) 265-293
  • 81 Tosi F, Negri C, Perrone F , et al. Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2012; 97 (5) 1712-1719
  • 82 Jakubowicz DJ, Nestler JE. 17 alpha-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 1997; 82 (2) 556-560
  • 83 Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335 (9) 617-623
  • 84 Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 1997; 82 (12) 4075-4079
  • 85 Ehrmann DA, Schneider DJ, Sobel BE , et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997; 82 (7) 2108-2116
  • 86 Moghetti P, Castello R, Negri C , et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85 (1) 139-146
  • 87 Komindr S, Kurtz BR, Stevens MD, Karas JG, Bittle JB, Givens JR. Relative sensitivity and responsivity of serum cortisol and two adrenal androgens to alpha-adrenocorticotropin-(1-24) in normal and obese, nonhirsute, eumenorrheic women. J Clin Endocrinol Metab 1986; 63 (4) 860-864
  • 88 Moghetti P, Castello R, Negri C , et al. Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 1996; 81 (3) 881-886
  • 89 Tosi F, Negri C, Brun E , et al. Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women. Eur J Endocrinol 2011; 164 (2) 197-203
  • 90 Romualdi D, Giuliani M, Draisci G , et al. Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic ovary syndrome. Fertil Steril 2007; 88 (1) 131-138
  • 91 Burger HG. Androgen production in women. Fertil Steril 2002; 77 (Suppl. 04) S3-S5
  • 92 Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W. Androgen generation in adipose tissue in women with simple obesity—a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. J Endocrinol 2004; 183 (2) 331-342
  • 93 Hirshfeld-Cytron J, Barnes RB, Ehrmann DA, Caruso A, Mortensen MM, Rosenfield RL. Characterization of functionally typical and atypical types of polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94 (5) 1587-1594
  • 94 Rosenfield RL, Mortensen M, Wroblewski K, Littlejohn E, Ehrmann DA. Determination of the source of androgen excess in functionally atypical polycystic ovary syndrome by a short dexamethasone androgen-suppression test and a low-dose ACTH test. Hum Reprod 2011; 26 (11) 3138-3146
  • 95 Stewart PM, Shackleton CH, Beastall GH, Edwards CR. 5 alpha-reductase activity in polycystic ovary syndrome. Lancet 1990; 335 (8687) 431-433
  • 96 Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates. J Clin Endocrinol Metab 2003; 88 (12) 5907-5913
  • 97 Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W. Beyond adrenal and ovarian androgen generation: increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88 (6) 2760-2766
  • 98 Vassiliadi DA, Barber TM, Hughes BA , et al. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009; 94 (9) 3558-3566
  • 99 Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone—>cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999; 84 (3) 1022-1027
  • 100 Rodin A, Thakkar H, Taylor N, Clayton R. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase. N Engl J Med 1994; 330 (7) 460-465
  • 101 DeBoer MD. Obesity, systemic inflammation, and increased risk for cardiovascular disease and diabetes among adolescents: a need for screening tools to target interventions. Nutrition 2013; 29 (2) 379-386
  • 102 Toulis KA, Goulis DG, Farmakiotis D , et al. Adiponectin levels in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Hum Reprod Update 2009; 15 (3) 297-307
  • 103 Gao L, Zhang Y, Cui Y, Jiang Y, Wang X, Liu J. Association of the T45G and G276T polymorphisms in the adiponectin gene with PCOS: a meta-analysis. Gynecol Endocrinol 2012; 28 (2) 106-110
  • 104 Lagaly DV, Aad PY, Grado-Ahuir JA, Hulsey LB, Spicer LJ. Role of adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol 2008; 284 (1-2) 38-45
  • 105 Munir I, Yen HW, Baruth T , et al. Resistin stimulation of 17alpha-hydroxylase activity in ovarian theca cells in vitro: relevance to polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90 (8) 4852-4857
  • 106 Barber TM, Franks S. Adipocyte biology in polycystic ovary syndrome. Mol Cell Endocrinol 2013; 373 (1-2) 68-76
  • 107 Roby KF, Terranova PF. Effects of tumor necrosis factor-alpha in vitro on steroidogenesis of healthy and atretic follicles of the rat: theca as a target. Endocrinology 1990; 126 (5) 2711-2718
  • 108 Spaczynski RZ, Arici A, Duleba AJ. Tumor necrosis factor-alpha stimulates proliferation of rat ovarian theca-interstitial cells. Biol Reprod 1999; 61 (4) 993-998
  • 109 Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993; 77 (6) 1690-1694
  • 110 Päth G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA. Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J Clin Endocrinol Metab 1997; 82 (7) 2343-2349
  • 111 Escobar-Morreale HF, Luque-Ramírez M, San Millán JL. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 2005; 26 (2) 251-282
  • 112 Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril 2011; 95 (3) 1048-1058 , e1–e2
  • 113 Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol 2011; 335 (1) 30-41
  • 114 Dumesic DA, Abbott DH, Padmanabhan V. Polycystic ovary syndrome and its developmental origins. Rev Endocr Metab Disord 2007; 8 (2) 127-141
  • 115 Abbott DH, Tarantal AF, Dumesic DA. Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am J Primatol 2009; 71 (9) 776-784
  • 116 Padmanabhan V, Veiga-Lopez A. Animal models of the polycystic ovary syndrome phenotype. Steroids 2013; 78 (8) 734-740
  • 117 Hickey M, Sloboda DM, Atkinson HC , et al. The relationship between maternal and umbilical cord androgen levels and polycystic ovary syndrome in adolescence: a prospective cohort study. J Clin Endocrinol Metab 2009; 94 (10) 3714-3720
  • 118 Anderson H, Fogel N, Grebe SK, Singh RJ, Taylor RL, Dunaif A. Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels. J Clin Endocrinol Metab 2010; 95 (5) 2180-2186
  • 119 Barry JA, Kay AR, Navaratnarajah R , et al. Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels. J Obstet Gynaecol 2010; 30 (5) 444-446
  • 120 Van Wagenen G. Accelerated growth with sexual precocity in female monkeys receiving testosterone propionate. Endocrinology 1949; 45 (5) 544-546
  • 121 McGee WK, Bishop CV, Bahar A , et al. Elevated androgens during puberty in female rhesus monkeys lead to increased neuronal drive to the reproductive axis: a possible component of polycystic ovary syndrome. Hum Reprod 2012; 27 (2) 531-540
  • 122 Diamanti-Kandarakis E, Bourguignon JP, Giudice LC , et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 2009; 30 (4) 293-342
  • 123 Eng DS, Lee JM, Gebremariam A, Meeker JD, Peterson K, Padmanabhan V. Bisphenol A and chronic disease risk factors in US children. Pediatrics 2013; 132 (3) e637-e645
  • 124 Zhou W, Liu J, Liao L, Han S, Liu J. Effect of bisphenol A on steroid hormone production in rat ovarian theca-interstitial and granulosa cells. Mol Cell Endocrinol 2008; 283 (1-2) 12-18
  • 125 Takeuchi T, Tsutsumi O, Ikezuki Y, Takai Y, Taketani Y. Positive relationship between androgen and the endocrine disruptor, bisphenol A, in normal women and women with ovarian dysfunction. Endocr J 2004; 51 (2) 165-169
  • 126 Barber TM, Bennett AJ, Groves CJ , et al. Association of variants in the fat mass and obesity associated (FTO) gene with polycystic ovary syndrome. Diabetologia 2008; 51 (7) 1153-1158
  • 127 Wehr E, Schweighofer N, Möller R, Giuliani A, Pieber TR, Obermayer-Pietsch B. Association of FTO gene with hyperandrogenemia and metabolic parameters in women with polycystic ovary syndrome. Metabolism 2010; 59 (4) 575-580
  • 128 Kowalska I, Malecki MT, Straczkowski M , et al. The FTO gene modifies weight, fat mass and insulin sensitivity in women with polycystic ovary syndrome, where its role may be larger than in other phenotypes. Diabetes Metab 2009; 35 (4) 328-331
  • 129 Ewens KG, Jones MR, Ankener W , et al. FTO and MC4R gene variants are associated with obesity in polycystic ovary syndrome. PLoS ONE 2011; 6 (1) e16390
  • 130 Tan S, Scherag A, Janssen OE , et al. Large effects on body mass index and insulin resistance of fat mass and obesity associated gene (FTO) variants in patients with polycystic ovary syndrome (PCOS). BMC Med Genet 2010; 11: 12
  • 131 Wojciechowski P, Lipowska A, Rys P , et al; GIANT Consortium. Impact of FTO genotypes on BMI and weight in polycystic ovary syndrome: a systematic review and meta-analysis. Diabetologia 2012; 55 (10) 2636-2645
  • 132 Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 2006; 91 (2) 492-497
  • 133 Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87 (3) 1017-1023
  • 134 Flannery CA, Rackow B, Cong X, Duran E, Selen DJ, Burgert TS. Polycystic ovary syndrome in adolescence: impaired glucose tolerance occurs across the spectrum of BMI. Pediatr Diabetes 2013; 14 (1) 42-49
  • 135 Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 2011; 95 (3) 1073-1079 , e1–e11
  • 136 Tasali E, Van Cauter E, Ehrmann DA. Polycystic ovary syndrome and obstructive sleep apnea. Sleep Med Clin 2008; 3 (1) 37-46
  • 137 de Sousa G, Schlüter B, Buschatz D , et al. A comparison of polysomnographic variables between obese adolescents with polycystic ovarian syndrome and healthy, normal-weight and obese adolescents. Sleep Breath 2010; 14 (1) 33-38
  • 138 Nandalike K, Agarwal C, Strauss T , et al. Sleep and cardiometabolic function in obese adolescent girls with polycystic ovary syndrome. Sleep Med 2012; 13 (10) 1307-1312
  • 139 Dokras A. Mood and anxiety disorders in women with PCOS. Steroids 2012; 77 (4) 338-341
  • 140 Trent ME, Rich M, Austin SB, Gordon CM. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med 2002; 156 (6) 556-560
  • 141 McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, Nemeroff CB. Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 2004; 65 (5) 634-651 , quiz 730
  • 142 Trent M, Austin SB, Rich M, Gordon CM. Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. Ambul Pediatr 2005; 5 (2) 107-111
  • 143 Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril 2007; 87 (6) 1369-1376
  • 144 Dieudonne MN, Pecquery R, Boumediene A, Leneveu MC, Giudicelli Y. Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids. Am J Physiol 1998; 274 (6 Pt 1) C1645-C1652
  • 145 Janssen I, Powell LH, Kazlauskaite R, Dugan SA. Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study. Obesity (Silver Spring) 2010; 18 (3) 604-610
  • 146 Lovejoy JC, Bray GA, Bourgeois MO , et al. Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women—a clinical research center study. J Clin Endocrinol Metab 1996; 81 (6) 2198-2203
  • 147 Elbers JM, Asscheman H, Seidell JC, Megens JA, Gooren LJ. Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab 1997; 82 (7) 2044-2047
  • 148 Gambineri A, Pelusi C, Genghini S , et al. Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004; 60 (2) 241-249
  • 149 Gambineri A, Patton L, Vaccina A , et al. Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 2006; 91 (10) 3970-3980
  • 150 Corbould A. Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?. Diabetes Metab Res Rev 2008; 24 (7) 520-532
  • 151 Korhonen S, Hippeläinen M, Vanhala M, Heinonen S, Niskanen L. The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study. Fertil Steril 2003; 79 (6) 1327-1334
  • 152 Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90 (4) 1929-1935
  • 153 Fruzzetti F, Perini D, Lazzarini V, Parrini D, Genazzani AR. Hyperandrogenemia influences the prevalence of the metabolic syndrome abnormalities in adolescents with the polycystic ovary syndrome. Gynecol Endocrinol 2009; 25 (5) 335-343
  • 154 Holmäng A, Svedberg J, Jennische E, Björntorp P. Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol 1990; 259 (4 Pt 1) E555-E560
  • 155 Holmäng A, Larsson BM, Brzezinska Z, Björntorp P. Effects of short-term testosterone exposure on insulin sensitivity of muscles in female rats. Am J Physiol 1992; 262 (6 Pt 1) E851-E855
  • 156 Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol 2007; 192 (3) 585-594
  • 157 Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994; 79 (1) 265-271
  • 158 Diamond MP, Grainger D, Diamond MC, Sherwin RS, Defronzo RA. Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab 1998; 83 (12) 4420-4425